Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis

ConclusionsDecreasing production of bFGF, PlGF or IL-6 by 1-year tofacitinib therapy potentially inhibits synovial and aortic inflammation. Although NT-proBNP, CXCL8 and CathK were associated with ccIMT, their role in RA-associated atherosclerosis needs to be further evaluated.
Source: Rheumatology - Category: Rheumatology Source Type: research